8:45am ET
Investing
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs
Secondary offerings from biotechs Immunovant, Kymera Therapeutics, and Wave Life Sciences prompted some huge insider buying recently.
Companies
/Healthcare
Immunovant Inc
$28.38
▼ $0.72 (−2.48%) today
Markets open · 2:22pm ET
24/7 Wall St. View
IMVT at a Glance
Valuation
- Market cap
- $6.0B
Profitability
- EPS (TTM)
- $-2.89
Price
- 52-week range
- $19 – $45
- Street target
- $48.88
Earnings
- Next report
- Nov 9, 2026
Headquartered in Durham, NC Fiscal year ends March NASDAQ: IMVT immunovant.com
About Immunovant
Immunovant, Inc. is a clinical-stage immunology company focused on developing therapies for autoimmune diseases. The company is a majority-owned subsidiary of Roivant Sciences (Nasdaq: ROIV). As a pioneer in anti-FcRn technology, Immunovant is developing IMVT-1402, its lead clinical-stage asset, across six autoimmune indications: Graves' disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis, Sjögren's disease, and cutaneous lupus erythematosus. The company is pre-revenue with no approved products and is currently funding operations through its cash reserves. Immunovant is listed on the Nasdaq under the ticker IMVT. Updated
Frequently Asked Questions
What does Immunovant do?
Immunovant, Inc. is a clinical-stage immunology company focused on developing therapies for autoimmune diseases. The company is a majority-owned subsidiary of Roivant Sciences (Nasdaq: ROIV).
What is the IMVT stock price target?
The Wall Street consensus 12-month price target for IMVT is $48.88. IMVT price prediction →